Literature DB >> 26545779

NOX1 mediates chemoresistance via HIF1α/MDR1 pathway in gallbladder cancer.

Ming Zhan1, Hui Wang1, Tao Chen1, Wei Chen1, Linhua Yang1, Min He1, Sunwang Xu1, Jian Wang2.   

Abstract

NADPH oxidase 1 (NOX1) plays a key role in tumorigenesis and metastasis through generating reactive oxygen species (ROS), an important intracellular signaling molecule. However, how it is expressed in gallbladder cancer (GBC) tissue sample and whether it associates with GBC chemoresistance have never been investigated. Our study analyzed the relationship between NOX1 expression and cisplatin-sensitivity both in vivo and in vitro. We found that reduced NOX1 expression promoted cisplatin efficiency in GBC-SD cells, whereas overexpression of which potentially inhibited the sensitivity of cisplatin in SGC-996 cells. Further study into the mechanism we found that increased NOX1 expression elevated intracellular ROS levels, which then activated HIF-1α/MDR1 pathway. These findings established NOX1 a novel accelerant of chemoresistance in GBC, and NOX1-targeted therapeutics might be exploited as a strategy for increasing the efficacy of cisplatin treatment.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Chemoresistance; Cisplatin; Gallbladder cancer; HIF1α; MDR1; NOX1

Mesh:

Substances:

Year:  2015        PMID: 26545779     DOI: 10.1016/j.bbrc.2015.10.161

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  11 in total

1.  miR-145 sensitizes gallbladder cancer to cisplatin by regulating multidrug resistance associated protein 1.

Authors:  Ming Zhan; Xiaonan Zhao; Hui Wang; Wei Chen; Sunwang Xu; Wei Wang; Hui Shen; Shuai Huang; Jian Wang
Journal:  Tumour Biol       Date:  2016-02-08

2.  Inhibition of mTOR Pathway by Rapamycin Decreases P-glycoprotein Expression and Spontaneous Seizures in Pharmacoresistant Epilepsy.

Authors:  Xiaosa Chi; Cheng Huang; Rui Li; Wei Wang; Mengqian Wu; Jinmei Li; Dong Zhou
Journal:  J Mol Neurosci       Date:  2017-02-22       Impact factor: 3.444

3.  Overexpression of DUOX2 mediates doxorubicin resistance and predicts prognosis of pancreatic cancer.

Authors:  Peng-Wei Lyu; Xiao-Dong Xu; Ke Zong; Xin-Guang Qiu
Journal:  Gland Surg       Date:  2022-01

4.  Claudin-6 increases SNAI1, NANOG and SOX2 gene expression in human gastric adenocarcinoma AGS cells.

Authors:  Priscila Anhel Medrano-Gonzálezl; Franklin Cruz-Villegas; Alejandro Alarcón Del Carmen; Luis Felipe Montaño; Erika Patricia Rendón-Huerta
Journal:  Mol Biol Rep       Date:  2022-09-28       Impact factor: 2.742

5.  miR-218-5p restores sensitivity to gemcitabine through PRKCE/MDR1 axis in gallbladder cancer.

Authors:  Hui Wang; Ming Zhan; Sun-Wang Xu; Wei Chen; Man-Mei Long; Yong-Heng Shi; Qiang Liu; Man Mohan; Jian Wang
Journal:  Cell Death Dis       Date:  2017-05-11       Impact factor: 8.469

Review 6.  Strange Bedfellows: Nuclear Factor, Erythroid 2-Like 2 (Nrf2) and Hypoxia-Inducible Factor 1 (HIF-1) in Tumor Hypoxia.

Authors:  Rachel K Toth; Noel A Warfel
Journal:  Antioxidants (Basel)       Date:  2017-04-06

7.  AEG-1 is associated with hypoxia-induced hepatocellular carcinoma chemoresistance via regulating PI3K/AKT/HIF-1alpha/MDR-1 pathway.

Authors:  Yong Xie; De-Wu Zhong
Journal:  EXCLI J       Date:  2016-11-30       Impact factor: 4.068

8.  Mitochondrial pyruvate carrier function is negatively linked to Warburg phenotype in vitro and malignant features in esophageal squamous cell carcinomas.

Authors:  Yaqing Li; Xiaoran Li; Quancheng Kan; Mingzhi Zhang; Xiaoli Li; Ruiping Xu; Junsheng Wang; Dandan Yu; Mariusz Adam Goscinski; Jian-Guo Wen; Jahn M Nesland; Zhenhe Suo
Journal:  Oncotarget       Date:  2017-01-03

Review 9.  Influence of microRNAs and Long Non-Coding RNAs in Cancer Chemoresistance.

Authors:  Duncan Ayers; Jo Vandesompele
Journal:  Genes (Basel)       Date:  2017-03-03       Impact factor: 4.096

10.  MBD1 promotes the malignant behavior of gallbladder cancer cells and induces chemotherapeutic resistance to gemcitabine.

Authors:  Liu Wensheng; Zhang Bo; Hu Qiangsheng; Xu Wenyan; Ji Shunrong; Xu Jin; Ni Quanxing; Yu Xianjun; Xu Xiaowu
Journal:  Cancer Cell Int       Date:  2019-09-09       Impact factor: 5.722

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.